Trials / Conditions / Aggressive Systemic Mastocytosis
Aggressive Systemic Mastocytosis
6 registered clinical trials studyying Aggressive Systemic Mastocytosis.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Completed | Retrospective Study Assessing the Effect of Avapritinib Versus Best Available Therapy in Patients With AdvSM NCT04695431 | Blueprint Medicines Corporation | — |
| Completed | (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted NCT03580655 | Blueprint Medicines Corporation | Phase 2 |
| Completed | (EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory NCT02561988 | Blueprint Medicines Corporation | Phase 1 |
| Terminated | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis NCT02415608 | Jason Robert Gotlib | Phase 2 |
| Completed | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia NCT01807598 | Jason Robert Gotlib | Phase 2 |
| No Longer Available | Managed Access Programs for PKC412, Midostaurin NCT05219266 | Novartis Pharmaceuticals | — |